Nonalcoholic fatty liver disease;Stéatopathies métaboliques

Presse Medicale

Volumn 41, Issue 2, 2012, Pages 169-189

  Lemoine, Maud ^a,b   Serfaty, Lawrence ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN SENSITIZING AGENT; LIVER PROTECTIVE AGENT;

CELL DAMAGE; CHRONIC LIVER DISEASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS; DIET; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; EPIDEMIC; EXERCISE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATIENT IDENTIFICATION; SHORT SURVEY;

ALGORITHMS; DISEASE PROGRESSION; FATTY LIVER; HUMANS;

EID: 84856314585     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.04.006     Document Type: Short Survey

References (175)

1. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
2. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55(7):434-438.
3. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123(5):1705-1725.
4. Le Roith D., Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001, 24(3):588-597.
5. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003, 278(5):2896-2902.
6. Hotamisligil G.S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245(6):621-625.
7. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51(12):3391-3399.
8. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003Apr 18, 278(16):13740-13746.
9. Klover P.J., Mooney R.A. Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell Biol 2004, 36(5):753-758.
10. Wallace T.M., Matthews D.R. The assessment of insulin resistance in man. Diabet Med 2002, 19(7):527-534.
11. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107(5):450-455.
12. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000.
13. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115(5):1343-1351.
14. Wang S., Soni K.G., Semache M., Casavant S., Fortier M., Pan L., et al. Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab 2008, 95(3):117-126.
15. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K.S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002, 35(4):898-904.
16. Day C.P., James O.F. Steatohepatitis: a tale of two " hits" ?. Gastroenterology 1998, 114(4):842-845.
17. Bedossa P., Houglum K., Trautwein C., Holstege A., Chojkier M. Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?. Hepatology 1994, 19(5):1262-1271.
18. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44(1):27-33.
19. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120(5):1183-1192.
20. Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Palu G., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol 2007, 292(2):G518-G525.
21. Kirsch R., Clarkson V., Verdonk R.C., Marais A.D., Shephard E.G., Ryffel B., et al. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 2006, 21(1Pt1):174-182.
22. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48(2):206-211.
23. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
24. Kammoun H.L., Chabanon H., Hainault I., Luquet S., Magnan C., Koike T., et al. GRP78expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009, 119(5):1201-1215.
25. Diehl A.M., Li Z.P., Lin H.Z., Yang S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54(2):303-306.
26. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40(1):46-54.
27. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30enhances hepatic insulin action. Nat Med 2001, 7(8):947-953.
28. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112(1):91-100.
29. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36(1):142-149.
30. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114(2):311-318.
31. Sumida Y., Nakashima T., Yoh T., Furutani M., Hirohama A., Kakisaka Y., et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003, 38(1):32-38.
32. Le Guenno G., Chanseaume E., Ruivard M., Morio B., Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract 2007, 77(3):363-370.
33. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006, 131(3):788-796.
34. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30(4):847-850.
35. Maher J.J., Leon P., Ryan J.C. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008, 48(2):670-678.
36. Li Z., Soloski M.J., Diehl A.M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42(4):880-885.
37. Guebre-Xabier M., Yang S., Lin H.Z., Schwenk R., Krzych U., Diehl A.M. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000, 31(3):633-640.
38. Kremer M. Hines IN. Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J Gastroenterol 2008, 14(3):487-488.
39. Elinav E., Pappo O., Sklair-Levy M., Margalit M., Shibolet O., Gomori M., et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8trapping. J Pathol 2006, 209(1):121-128.
40. Costet P., Legendre C., More J., Edgar A., Galtier P., Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998, 273(45):29577-29585.
41. Boelsterli U.A., Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2diabetes. Biochem Pharmacol 2002, 63(1):1-10.
42. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119(2):466-478.
43. Hazra S., Xiong S., Wang J., Rippe R.A., Krishna V., Chatterjee K., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004, 279(12):11392-11401.
44. Lemoine M., Barbu V., Girard P.M., Kim M., Bastard J.P., Wendum D., et al. Altered hepatic expression of SREBP-1and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006, 20(3):387-395.
45. McClain C.J., Barve S., Deaciuc I. Good fat/bad fat. Hepatology 2007, 45(6):1343-1346.
46. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45(6):1366-1374.
47. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
48. Feldstein A.E., Canbay A., Guicciardi M.E., Higuchi H., Bronk S.F., Gores G.J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003, 39(6):978-983.
49. Syn W.K., Jung Y., Omenetti A., Abdelmalek M., Guy C.D., Yang L., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137(4):1478-1488. [e8].
50. Charles M.A., Eschwege E., Basdevant A. Monitoring the obesity epidemic in France: the Obepi surveys 1997-2006. Obesity (Silver Spring) 2008, 16(9):2182-2186.
51. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132(2):112-117.
52. Clark J.M., Brancati F.L., Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 2002, 122(6):1649-1657.
53. Fracanzani A.L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48(3):792-798.
54. Hilden M., Christoffersen P., Juhl E., Dalgaard J.B. Liver histology in a 'normal' population--examinations of 503consecutive fatal traffic casualties. Scand J Gastroenterol 1977, 12(5):593-597.
55. Nomura H., Kashiwagi S., Hayashi J., Kajiyama W., Tani S., Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J M 1988, 27(2):142-149.
56. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42(1):44-52.
57. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
58. Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
59. Zhou Y.J., Li Y.Y., Nie Y.Q., Ma J.X., Lu L.G., Shi S.L., et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007, 13(47):6419-6424.
60. Amarapurkar D., Kamani P., Patel N., Gupte P., Kumar P., Agal S., et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007, 6(3):161-163.
61. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
62. Mathurin P., Gonzalez F., Kerdraon O., Leteurtre E., Arnalsteen L., Hollebecque A., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006, 130(6):1617-1624.
63. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
64. de Ledinghen V., Ratziu V., Causse X., Le Bail B., Capron D., Renou C., et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 2006, 45(4):592-599.
65. Serfaty L., Andreani T., Giral P., Carbonell N., Chazouilleres O., Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001, 34(3):428-434.
66. Bedossa P., Moucari R., Chelbi E., Asselah T., Paradis V., Vidaud M., et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007, 46(2):380-387.
67. Ingiliz P., Valantin M.A., Duvivier C., Medja F., Dominguez S., Charlotte F., et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1mono-infected patients on antiretroviral therapy. Hepatology 2009, 49(2):436-442.
68. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22(6):1714-1719.
69. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21years. Hepatology 1990, 11(1):74-80.
70. Contos M.J., Cales W., Sterling R.K., Luketic V.A., Shiffman M.L., Mills A.S., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001, 7(4):363-373.
71. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22(3):222-226.
72. Serfaty L., Poujol-Robert A., Carbonell N., Chazouilleres O., Poupon R.E., Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002, 97(7):1807-1812.
73. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107(4):1103-1109.
74. Lee R.G. Nonalcoholic steatohepatitis: a study of 49patients. Hum Pathol 1989, 20(6):594-598.
75. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
76. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103patients with sequential liver biopsies. J Hepatol 2005, 42(1):132-138.
77. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
78. Fassio E., Alvarez E., Dominguez N., Landeira G., Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40(4):820-826.
79. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98(9):2042-2047.
80. Caldwell S.H., Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004, 40(4):578-584.
81. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006, 12(4):523-534.
82. Ioannou G.N., Weiss N.S., Kowdley K.V., Dominitz J.A. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003, 125(4):1053-1059.
83. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38(2):420-427.
84. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35(6):1485-1493.
85. Sanyal A.J., Banas C., Sargeant C., Luketic V.A., Sterling R.K., Stravitz R.T., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43(4):682-689.
86. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-140.
87. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
88. Nair S., Mason A., Eason J., Loss G., Perrillo R.P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002, 36(1):150-155.
89. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36(6):1349-1354.
90. Gonzalez L., Blanc J.F., Sa Cunha A., Rullier A., Saric J., Le Bail B., et al. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 2004, 24(4):415-419.
91. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49(3):851-859.
92. Yang S., Lin H.Z., Hwang J., Chacko V.P., Diehl A.M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Res 2001, 61(13):5016-5023.
93. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
94. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
95. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
96. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2diabetic patients. Diabetes Care 2007, 30(8):2119-2121.
97. Goessling W., Massaro J.M., Vasan R.S., D'Agostino R.B., Ellison R.C., Fox C.S. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135(6):1935-1944. [e1].
98. Targher G., Bertolini L., Padovani R., Rodella S., Arcaro G., Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007, 46(6):1126-1132.
99. Perseghin G., Lattuada G., De Cobelli F., Esposito A., Belloni E., Ntali G., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47(1):51-58.
100. Wannamethee S.G., Shaper A.G., Lennon L., Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2diabetes in older men. Diabetes Care 2005, 28(12):2913-2918.
101. Ryysy L., Hakkinen A.M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2diabetic patients. Diabetes 2000, 49(5):749-758.
102. Newton J.L., Jones D.E., Henderson E., Kane L., Wilton K., Burt A.D., et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008, 57(6):807-813.
103. Ayata G., Gordon F.D., Lewis W.D., Pomfret E., Pomposelli J.J., Jenkins R.L., et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002, 33(11):1098-1104.
104. Caldwell S.H., Hespenheide E.E. Subacute liver failure in obese women. Am J Gastroenterol 2002, 97(8):2058-2062.
105. Moirand R., Mortaji A.M., Loreal O., Paillard F., Brissot P., Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997, 349(9045):95-97.
106. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004, 39(1):179-187.
107. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
108. Piccinino F., Sagnelli E., Pasquale G., Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276biopsies. J Hepatol 1986, 2(2):165-173.
109. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
110. Oh S.Y., Cho Y.K., Kang M.S., Yoo T.W., Park J.H., Kim H.J., et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006, 55(12):1604-1609.
111. Mehta S.R., Thomas E.L., Bell J.D., Johnston D.G., Taylor-Robinson S.D. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008, 14(22):3476-3483.
112. Mazhar S.M., Shiehmorteza M., Sirlin C.B. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009, 7(2):135-140.
113. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123(3):745-750.
114. Thomas E.L., Hamilton G., Patel N., O'Dwyer R., Dore C.J., Goldin R.D., et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005, 54(1):122-127.
115. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005, 4:10.
116. Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L.M., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137(3):865-872.
117. Palekar N.A., Naus R., Larson S.P., Ward J., Harrison S.A. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006, 26(2):151-156.
118. Shimada M., Kawahara H., Ozaki K., Fukura M., Yano H., Tsuchishima M., et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007, 102(9):1931-1938.
119. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50(4):1072-1078.
120. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009.
121. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713.
122. Cales P., Laine F., Boursier J., Deugnier Y., Moal V., Oberti F., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009, 50(1):165-173.
123. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007, 7:40.
124. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118(6):1117-1123.
125. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854.
126. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008, 48(5):835-847.
127. Yoneda M., Yoneda M., Mawatari H., Fujita K., Endo H., Iida H., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008, 40(5):371-378.
128. Nobili V., Vizzutti F., Arena U., Abraldes J.G., Marra F., Pietrobattista A., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48(2):442-448.
129. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan H.L., Le Bail B., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2010, 51(2):454-462.
130. Castera L., Foucher J., Bernard P.H., Carvalho F., Allaix D., Merrouche W., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology (Baltimore, Md) 2010, 51(3):828-835.
131. de Ledinghen V., Vergniol J., Foucher J., El-Hajbio F., Merrouche W., Rigalleau V., et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010, 30(7):1043-1048.
132. Johnson N.A., Sachinwalla T., Walton D.W., Smith K., Armstrong A., Thompson M.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50(4):1105-1112.
133. Dixon J.B., Bhathal P.S., Hughes N.R., O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39(6):1647-1654.
134. Wang R.T., Koretz R.L., Yee H.F. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003, 115(7):554-559.
135. Huang M.A., Greenson J.K., Chao C., Anderson L., Peterman D., Jacobson J., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100(5):1072-1081.
136. Zelber-Sagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4(5):639-644.
137. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397.
138. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292(14):1724-1737.
139. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009.
140. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6(9):998-1003.
141. Nair S., Diehl A.M., Wiseman M., Farr G.H., Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004, 20(1):23-28.
142. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358(9285):893-894.
143. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100(5):1082-1090.
144. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab 2001, 27(3):305-313.
145. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39(1):188-196.
146. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38(4):1008-1017.
147. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355(22):2297-2307.
148. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4):1176-1184.
149. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135(1):100-110.
150. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685.
151. Henriksen J.H., Ring-Larsen H. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). J Hepatol 2008, 48(1):174-176.
152. Teixeira-Clerc F., Julien B., Grenard P., Tran Van Nhieu J., Deveaux V., Li L., et al. CB1cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12(6):671-676.
153. Modica S., Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett 2006, 580(23):5492-5499.
154. Sanyal A. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study. Hepatology 2009, 50(Suppl.):389A.
155. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23(6):1464-1467.
156. Lindor K.D., Kowdley K.V., Heathcote E.J., Harrison M.E., Jorgensen R., Angulo P., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
157. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2diabetes. Science 2006, 313(5790):1137-1140.
158. Ratziu V. Multicentric, double-blind, randomised-controlled trial (RCT) of high dose ursodeoxycholic acid in patients with NASH. Hepatology 2009, 50(Suppl.1):49.
159. Leuschner U.F., Lindenthal B., Herrmann G., Arnold J.C., Rossle M., Cordes H.J., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(2):472-479.
160. Balmer M.L., Siegrist K., Zimmermann A., Dufour J.F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009, 29(8):1184-1188.
161. Laurent A., Nicco C., Tran Van Nhieu J., Borderie D., Chereau C., Conti F., et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004, 39(5):1277-1285.
162. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvestre P.B., Lindor K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96(9):2711-2717.
163. Oliveira C.P., Gayotto L.C., Tatai C., Della Nina B.I., Lima E.S., Abdalla D.S., et al. Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats. Nutr J 2003, 2:9.
164. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2(12):1107-1115.
165. Adams L.A., Zein C.O., Angulo P., Lindor K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99(12):2365-2368.
166. Satapathy S.K., Garg S., Chauhan R., Sakhuja P., Malhotra V., Sharma B.C., et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99(10):1946-1952.
167. Satapathy S.K., Sakhuja P., Malhotra V., Sharma B.C., Sarin S.K. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22(5):634-638.
168. Valenti L., Fracanzani A.L., Dongiovanni P., Bugianesi E., Marchesini G., Manzini P., et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007, 102(6):1251-1258.
169. Huang Q., Xie Q., Shi C.C., Xiang X.G., Lin L.Y., Gong B.D., et al. Expression of angiotensin-converting enzyme 2in CCL4-induced rat liver fibrosis. Int J Mol Med 2009, 23(6):717-723.
170. Saiki A., Ohira M., Endo K., Koide N., Oyama T., Murano T., et al. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2diabetes mellitus. Metabolism 2009, 58(5):708-713.
171. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40(5):1222-1225.
172. Witek R.P., Stone W.C., Karaca F.G., Syn W.K., Pereira T.A., Agboola K.M., et al. Pan-caspase inhibitor VX-166reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50(5):1421-1430.
173. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37(4):909-916.
174. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48(6):993-999.
175. Special Conference on NAFLD/NASH and Related Metabolic Disease. Septembre 24-26, Bologna, Italy; 2009.